Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan
The analysis demonstrated that universal prophylaxis strategy with nirsevimab would significantly reduce the health and economic burden associated with RSV among infants in Japan. At the assumed price, nirsevimab can provide a cost-effective prophylaxis option against RSV infection in an all-infant population not limited to infants born prematurely or with high risk.
Authors
- Samira Soudani (ORCID: https://orcid.org/0009-0006-4523-6588)
- Takeshi Arashiro (ORCID: https://orcid.org/0000-0002-5215-1500)
- Shinichi Noto (ORCID: https://orcid.org/0000-0002-6952-7770)
- Xinyu Wang (ORCID: https://orcid.org/0009-0009-3151-8092)
- Alexia Kieffer (ORCID: https://orcid.org/0009-0004-5735-195X)
- S. Eymere (ORCID: https://orcid.org/0000-0001-8074-5480)
- Tobiasz Lemański
- Chiho Tadera
Institutions
- Sanofi (France) (FR)
- Sanofi (Japan) (JP)
- Niigata University of Health and Welfare (JP)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s40121-025-01134-1
- Citations
- 9
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 12.19
Funders
- Sanofi K.K.